{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:31:03Z","timestamp":1757705463335},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11255-018-1940-8","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T11:26:46Z","timestamp":1533209206000},"page":"2201-2206","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis"],"prefix":"10.1007","volume":"50","author":[{"given":"Dengpiao","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"6","key":"1940_CR1","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67(6):2089\u20132100","journal-title":"Kidney Int"},{"issue":"9818","key":"1940_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","volume":"379","author":"Y Yano","year":"2012","unstructured":"Yano Y, Fujimoto S, Asahi K et al (2012) Prevalence of chronic kidney disease in China. Lancet 379(9818):815","journal-title":"Lancet"},{"issue":"3","key":"1940_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00041552-200205000-00011","volume":"11","author":"CY Hsu","year":"2002","unstructured":"Hsu CY (2002) Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 11(3):337","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"1940_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2007.06.008","volume":"50","author":"A Levin","year":"2007","unstructured":"Levin A, Rocco M (2007) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis 50(3):471\u2013530","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"1940_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23(10):1631\u20131634","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1940_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","volume":"67","author":"M Bonomini","year":"2016","unstructured":"Bonomini M, Del Vecchio L, Sirolli V et al (2016) New treatment approaches for the anemia of CKD. Am J Kidney Dis 67(1):133\u2013142","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1940_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000045834","volume":"86","author":"J M\u00f6cks","year":"2000","unstructured":"M\u00f6cks J (2000) Cardiovascular mortality in haemodialysis patients treated with epoetin beta\u2014a retrospective study. Nephron 86(4):455\u2013462","journal-title":"Nephron"},{"issue":"6","key":"1940_CR8","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1681\/ASN.2004070597","volume":"16","author":"DE Weiner","year":"2005","unstructured":"Weiner DE, Tighiouart H, Vlagopoulos PT et al (2005) Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16(6):1803","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1940_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000186829","volume":"61","author":"C Zehnder","year":"1992","unstructured":"Zehnder C, Zuber M, Sulzer M et al (1992) Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 61(1):21","journal-title":"Nephron"},{"issue":"9","key":"1940_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton WK, Browne JK et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339(9):584","journal-title":"N Engl J Med"},{"issue":"107","key":"1940_CR11","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/sj.ki.5002481","volume":"72","author":"K Iseki","year":"2007","unstructured":"Iseki K, Kohagura K (2007) Anemia as a risk factor for chronic kidney disease. Kidney Int 72(107):S4\u2013S9","journal-title":"Kidney Int"},{"issue":"4","key":"1940_CR12","first-page":"235","volume":"8","author":"TB Horwich","year":"2002","unstructured":"Horwich TB, Fonarow GC, Hamilton MA et al (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 8(4):235\u2013236","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1940_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/13543784.2016.1182981","volume":"25","author":"H Schmid","year":"2016","unstructured":"Schmid H, Jelkmann W (2016) Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs 25(8):901\u2013916","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"1940_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/dta.390","volume":"4","author":"S Beuck","year":"2012","unstructured":"Beuck S, Sch\u00e4nzer W, Thevis M (2012) Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal 4(11):830\u2013845","journal-title":"Drug Test Anal"},{"issue":"6","key":"1940_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","volume":"30","author":"K Hara","year":"2015","unstructured":"Hara K, Takahashi N, Wakamatsu A et al (2015) Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet 30(6):410\u2013418","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"1940_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","volume":"69","author":"N Gupta","year":"2017","unstructured":"Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69(6):815\u2013826","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1940_CR17","first-page":"S38","volume":"5","author":"J Higgins","year":"2011","unstructured":"Higgins J, Green SE (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. Naunyn-Schmiedebergs Archiv f\u00fcr experimentelle Pathologie und Pharmakologie 5(2):S38","journal-title":"Naunyn-Schmiedebergs Archiv f\u00fcr experimentelle Pathologie und Pharmakologie"},{"issue":"4","key":"1940_CR18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","volume":"27","author":"L Holdstock","year":"2016","unstructured":"Holdstock L, Meadowcroft AM, Maier R et al (2016) Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 27(4):1234","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1940_CR19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","volume":"67","author":"RA Brigandi","year":"2016","unstructured":"Brigandi RA, Johnson B, Oei C et al (2016) A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis 67(6):861\u2013871","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1940_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","volume":"45","author":"T Akizawa","year":"2016","unstructured":"Akizawa T, Tsubakihara Y, Nangaku M et al (2016) Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol 45(2):127","journal-title":"Am J Nephrol"},{"issue":"Suppl 2","key":"1940_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/ndt\/14.suppl_2.29","volume":"14","author":"JF Mann","year":"1999","unstructured":"Mann JF (1999) What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 14(Suppl 2):29","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1940_CR22","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1097\/01.ASN.0000018409.45834.FA","volume":"13","author":"WM Mcclellan","year":"2002","unstructured":"Mcclellan WM, Flanders WD, Langston RD et al (2002) Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13(7):1928","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1940_CR23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/ki.2008.299","volume":"74","author":"F Locatelli","year":"2008","unstructured":"Locatelli F, Nissenson AR, Barrett BJ et al (2008) Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 74(10):1237","journal-title":"Kidney Int"},{"issue":"20","key":"1940_CR24","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"National Kidney Foundation","year":"2006","unstructured":"National Kidney Foundation (2006) Correction of anemia with Epoetin Alfa in chronic kidney disease. NEJM N Engl J Med 355(20):2085\u20132098","journal-title":"NEJM N Engl J Med"},{"issue":"5","key":"1940_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/gut.2003.022863","volume":"53","author":"H Kulaksiz","year":"2004","unstructured":"Kulaksiz H, Gehrke SG, Janetzko A et al (2004) Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 53(5):735\u2013743","journal-title":"Gut"},{"issue":"15","key":"1940_CR26","doi-asserted-by":"publisher","first-page":"8780","DOI":"10.1073\/pnas.151179498","volume":"98","author":"G Nicolas","year":"2001","unstructured":"Nicolas G, Bennoun M, Devaux I et al (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98(15):8780","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1940_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI0215686","volume":"110","author":"G Nicolas","year":"2002","unstructured":"Nicolas G, Chauvet C, Viatte L et al (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Investig 110(7):1037","journal-title":"J Clin Investig"},{"issue":"4","key":"1940_CR28","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.ajkd.2009.12.030","volume":"55","author":"JL Babitt","year":"2010","unstructured":"Babitt JL, Lin HY (2010) Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 55(4):726","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1940_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000098522","volume":"30","author":"J Malyszko","year":"2007","unstructured":"Malyszko J, Mysliwiec M (2007) Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30(1):15\u201330","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"1940_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00467-014-2991-4","volume":"30","author":"MA Atkinson","year":"2015","unstructured":"Atkinson MA, Kim JY, Roy CN et al (2015) Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr Nephrol 30(4):635\u2013643","journal-title":"Pediatr Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-018-1940-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1940-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1940-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T23:26:25Z","timestamp":1564701985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-018-1940-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1007\/s11255-018-1940-8","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]},"assertion":[{"value":"10 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}},{"value":"Informed consent was obtained from all individual participants included the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}